Bio-Path Holdings (BPTH)
OTHER OTC:BPTH
Want to see BPTH full AI Analyst Report?
BPTH Stock Chart & Stats
$0.05
-$0.06(-5.61%)
At close: 4:00 PM EST
$0.05
-$0.06(-5.61%)
Day’s Range― - ―
52-Week Range$0.01 - $0.23
Previous CloseN/A
Volume216.71K
Average Volume (3M)24.92K
Market Cap
$326.98K
Enterprise Value$789.98K
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$463.00K
Price to Earnings (P/E)―
Beta-0.63
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding9,342,151
10 Day Avg. Volume24,655
30 Day Avg. Volume24,916
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap2.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.88
Enterprise Value/Ebitda-0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Liposomal Delivery Platform (DNAbilize)A proprietary liposomal delivery platform for RNAi therapeutics is a durable competitive asset: it can improve intracellular delivery, broaden targetability across oncology indications, and enhance partner interest. This platform-level advantage increases long-term clinical and licensing optionality.
Low Absolute Debt BurdenVery low reported debt reduces fixed financing obligations and short-term refinancing risk, giving management more flexibility to prioritize R&D and partner negotiations. In a capital-hungry biotech, low leverage materially lowers near-term liquidity stress versus high-debt peers.
Material Reduction In Cash Burn In 2025A significant decline in annual cash burn indicates improved cost discipline or program prioritization, extending runway and lowering immediate financing needs. Sustained lower burn increases probability of completing key clinical milestones or striking collaborations before further dilution.
Bears Say
No Revenue And Persistent Net LossesMulti-year absence of commercial revenue and recurring large net losses make the company dependent on external funding and high execution. Without approved products or licensing revenues, sustainable cash generation is uncertain and contingent on successful clinical outcomes.
Negative Shareholders' Equity And Asset DepletionNegative equity and collapsed asset base signal substantial capital depletion and weaken balance-sheet flexibility. This condition constrains financing options, may increase cost of capital, and elevates dilution or restructuring risk if additional funds are required to sustain operations.
Dependence On External Financing With No Recurring Product RevenueReliance on equity issuances and one-time financings ties survival to capital markets and dilutive funding rounds. Without commercial products or firm licensing deals, the company must continually access external capital, making long-term strategy vulnerable to market conditions and execution timing.
Bio-Path Holdings News
BPTH FAQ
What was Bio-Path Holdings’s price range in the past 12 months?
Bio-Path Holdings lowest stock price was $0.01 and its highest was $0.23 in the past 12 months.
What is Bio-Path Holdings’s market cap?
Bio-Path Holdings’s market cap is $326.98K.
When is Bio-Path Holdings’s upcoming earnings report date?
Bio-Path Holdings’s upcoming earnings report date is Aug 18, 2026 which is in 93 days.
How were Bio-Path Holdings’s earnings last quarter?
Currently, no data Available
Is Bio-Path Holdings overvalued?
According to Wall Street analysts Bio-Path Holdings’s price is currently Overvalued.
Does Bio-Path Holdings pay dividends?
Bio-Path Holdings does not currently pay dividends.
What is Bio-Path Holdings’s EPS estimate?
Bio-Path Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Path Holdings have?
Bio-Path Holdings has 9,342,151 shares outstanding.
What happened to Bio-Path Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bio-Path Holdings?
Currently, no hedge funds are holding shares in BPTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio-Path Holdings
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
2.70% Other Institutional Investors
97.30% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---